Abstract:The fifth wave of A(H7N9) virus infection in China from 2016 to 2017 caused great concern due to the large number of individuals infected, the isolation of drug-resistant viruses and emergence of highly pathogenic strains. Antibodies against neuraminidase (NA) provide added benefit to hemagglutinin-specific immunity and may be an important contributor to the effectiveness of A(H7N9) vaccines. We generated a panel of mouse monoclonal antibodies (MAbs) to identify antigenic domains on NA of the novel A(H7N9) virus and compared their functional properties. Two major antigenic regions, i.e., the 250-loop and 370/400/430-loop domains, were identified. MAbs 1E8, 2F6, 10F4 and 11B2, which recognize these 2 antigenic domains, were characterized in depth. These 4 MAbs differ in ability to inhibit cleavage of small and large substrates (MU-NANA and fetuin, respectively) in NA inhibition assays. 1E8 and 11B2 did not inhibit NA cleavage of either MU-NANA or fetuin, 2F6 inhibited cleavage of fetuin alone, whereas 10F4 inhibited cleavage of both substrates. All 4 MAbs reduced the in vitro spread of viruses carrying either the wild-type N9 or N9 with antiviral-resistant mutations, but to different degrees. These MAbs have different in vivo effectiveness, 10F4 was the most effective in protecting mice against challenge with A(H7N9) virus, 2F6 was less effective and 11B2 failed to protect BALB/c mice at the doses tested. Our study confirms that NA-specific antibodies can protect against A(H7N9) infection, and suggests that in vitro properties can be used to rank antibodies with therapeutic potential.IMPORTANCE The novel A(H7N9) viruses that emerged in China in 2013 continue to infect humans, with a high fatality rate. The most recent outbreak resulted in larger number of human cases than previous epidemic waves. Due to the absence of a licensed vaccine and emergence of drug-resistant viruses, there is a need to develop alternative approaches to prevent or treat A(H7N9) infection. We have made a panel of mouse monoclonal antibodies (MAbs) specific for neuraminidase (NA) of A(H7N9) viruses, some of these MAbs are effective in inhibiting viruses that are resistant to antivirals used to treat A(H7N9) patients. Binding avidity, inhibition of NA activity and plaque formation correlated with the effectiveness of these MAbs to protect mice against lethal A(H7N9) virus challenge. This study identifies in vitro measures that can be used to predict the in vivo efficacy of NA-specific antibodies, providing a way to select MAbs for further therapeutic development.

Identification of key residues involved in the neuraminidase antigenic variation of H9N2 influenza virus

Identification of catalytically active domain epitopes in neuraminidase protein of H9N2 subtype of avian influenza virus

Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses.

The amino acid variation at hemagglutinin sites 145, 153, 164 and 200 modulate antigenicity andreplication of H9N2 avian influenza virus

Genetic evolution analysis of hemagglutinin and neuraminidase genes of H9N2 avian influenza virus in external environment of some areas of Yunnan Province, China from 2020 to 2023

Identification of amino acids in highly pathogenic avian influenza H5N1 virus hemagglutinin that determine avian influenza species specificity

Comparison of the Efficacy of N9 Neuraminidase-specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.

Evaluation on the Receptor-Binding Preference and Drug Resistance of H9N2 Influenza Viruses

Characterization of Neutralizing Monoclonal Antibodies and Identification of a Novel Conserved C-Terminal Linear Epitope on the Hemagglutinin Protein of the H9N2 Avian Influenza Virus

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Mutation of the Second Sialic Acid-Binding Site, Resulting in Reduced Neuraminidase Activity, Preceded the Emergence of H7N9 Influenza A Virus.

HA gene amino acid mutations contribute to antigenic variation and immune escape of H9N2 influenza virus

Sequence Analysis of Neuraminidase Genes of 63 H9N2 Subtypes Avian Influenza Viruses

Assessing the Effects of a Two-Amino Acid Flexibility in the Hemagglutinin 220-Loop Receptor-Binding Domain on the Fitness of Influenza A(H9N2) Viruses

Single-amino-acid Mutation in the HA Alters the Recognition of H9N2 Influenza Virus by a Monoclonal Antibody

Identification of Critical Residues of Influenza Neuraminidase in Viral Particle Release

Phylogenetic Analysis of Neuraminidase Gene of H9N2 Influenza Viruses Prevalent in Chickens in China During 1995–2002

The Neuraminidase of A(H3N2) Influenza Viruses Circulating Since 2016 is Antigenically Distinct from the A/Hong Kong/4801/2014 Vaccine Strain

Amino Acid Variation at Hemagglutinin Position 193 Impacts the Properties of H9N2 Avian Influenza Virus

Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase

Mutations of 127, 183 and 212 Residues on the HA Globular Head Affect the Antigenicity, Replication and Pathogenicity of H9N2 Avian Influenza Virus